Ocugen (OCGN)

Last close As at 03/11/2025

USD1.54

−0.02 (−1.28%)

Market capitalisation

USD456m

Ocugen is a clinical-stage biotechnology company developing novel gene therapies to treat blinding retinal diseases, and its subsidiary is advancing cell therapies for orthopaedic indications.

Latest Insights

Healthcare | Quickview

Ocugen — Novel cell therapies for retinal diseases

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Director, healthcare

Key Management

  • Shankar Musunuri

    CEO

  • Ramesh Ramachandran

    Chief Accounting Officer

Thematics